Introduction {#sec1}
============

Depersonalization disorder (DPD) is a psychiatric syndrome characterized by persistent and distressing feelings of unreality and alterations in a person\'s sense of self [@bib1] as defined in DSM-IV-TR [@bib2]. It is found in many cultures [@bib3] and the condition affects around 1% of the population [@bib4]. It often begins in adolescence and has a tendency for chronicity [@bib5; @bib6]. Depersonalization is frequently a transient phenomenon in states of fatigue or fear [@bib7] and can appear as a symptom of other psychiatric disorders including panic disorder [@bib8]. Secondary forms are also well described in patients with neurological conditions, such as temporal lobe epilepsy [@bib9] and following substance misuse [@bib10; @bib11]. A variety of pharmacological treatments have been tried [@bib12] but most fail to show substantial benefits [@bib13]. A cognitive behavioral model has been developed [@bib14] but has not been subjected to a randomized controlled trial [@bib15].

A neurobiological model of DPD has also been proposed [@bib16], hypothesizing dysfunctionally increased fronto-insula/limbic inhibitory regulation. This model is consistent with neurological case studies [@bib17] and has been refined by neuroimaging research using fMRI [@bib18; @bib19], which has demonstrated reduced insula, limbic and visual association cortical activation in response to emotive pictures, and increased VLPFC activation. Psychophysiological studies using skin conductance response (SCR) measures [@bib20] have found reduced autonomic responses in patients with DPD to unpleasant, emotive stimuli, in comparison to those with anxiety disorders and to healthy controls [@bib21]. Work combining fMRI and SCR has shown a correlation between dorsolateral and ventral prefrontal and 'limbic' activation in response to emotional faces in DPD [@bib22; @bib23] which is consistent with the functional (reciprocal) interaction seen between VLPFC and insula in healthy volunteers [@bib24], and patients with anxiety states [@bib25]. Finally, preliminary work [@bib26] shows that reduced right VLPFC (and increased insula) activation on fMRI corresponds to symptomatic improvement in DPD patients treated with lamotrigine [@bib27]. This body of work appears to point to a mechanism for the emotional numbing frequently experienced by DPD suffers and may even relate to a core abnormal experiencing of the sense of self [@bib28].

Transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique, is well established both as a research tool and therapeutic intervention in a range of psychiatric disorder [@bib29]. Of relevance to DPD, rTMS has been used to examine the role of the prefrontal cortex in emotional regulation. A single session of rTMS to the right DLPFC induced impairments in participants\' ability to inhibit negative emotion processing in a facial evaluation task [@bib30]. Other studies found that low frequency (inhibitory) rTMS to the right DLPFC in healthy participants could induce risk-taking behavior on a gambling paradigm [@bib31] and reduce participants\' willingness to reject unfair offers on 'the ultimatum game' [@bib32; @bib33]. High frequency (excitatory) rTMS to the left DLPFC can reduce food craving [@bib34], cigarette smoking [@bib35] and cocaine craving [@bib36] compared to sham TMS. These studies indicate that rTMS can modulate behavior and motivational states by enhancing or attenuating inhibitory prefrontal mechanisms.

There have been two single case reports, and one trial reporting the usage of TMS in DPD. The first was a woman with co-morbid DPD and major depression (MDD) [@bib37] whose single photon emission computed tomography (SPECT) scan showed right frontal hyperactivity, which was the target of 1Hz rTMS. It was reported that her self-awareness increased and depersonalization symptoms decreased. In a second case study, a 24 year-old male with comorbid DPD and MDD who had not responded to pharmacotherapy also received an SPECT scan [@bib38]. The scan showed hypoperfusion bi-temporally and in the left frontoparietal region. rTMS was delivered to the left DLPFC, and a 28% reduction in symptoms was reported after 6 sessions. Finally, a trial in twelve DPD patients reported that half responded to temporal parietal junction (TPJ) TMS after three weeks of treatment [@bib39]. The TPJ region was chosen due to its relevance in out of body experiences (OBEs), researched previously using TMS [@bib40; @bib41]. Five out of the six responders showed a 68% reduction in symptoms after a total of six weeks treatment. Unfortunately, none of these studies utilized either sham or active control conditions, so it is not possible to exclude placebo effects. In addition there was no offline-testing of behavioral or physiological markers.

The overall aims of this research were to firstly use low frequency TMS stimulation to test a neurobiological model of DPD, whereby the VLPFC was the target site of stimulation, the TPJ taking the role as active control site of stimulation, and secondly compare the potential therapeutic utility of these two sites of stimulation for future controlled clinical trials in DPD. We chose VLPFC rather than DLPFC because of the balance of evidence pointing to the former in DPD reviewed above, and its role in regulation of abnormal states of anxiety and arousal [@bib25] despite the greater experience of TMS delivered to the DLPFC, and the likelihood that DLPFC as well as ventral and indeed medial frontal regions are also involved in emotion modulation [@bib42].

We sought to test the hypothesis that low frequency (inhibitory) rTMS to the right VLPFC in patients with DPD would cause increases in autonomic arousal (SCRs) and decreases is symptoms of DPD.

Methods and materials {#sec2}
=====================

Ethical approval {#sec2.1}
----------------

NHS Research Ethics Review System, London, approved this research in accordance with the declaration of Helsinki. All participants gave written informed consent.

Participants {#sec2.2}
------------

There were *N* = 43 participants in total: 22 had a primary diagnosis of DPD (DSM-IV TR) based on a detailed interview by the clinic psychiatrist. Patients were recruited through the Depersonalization Unit Clinic, a specialist outpatients service based at the Maudsley Hospital, South London. There were 21 healthy controls; these were staff and students of King\'s College London and local residents who responded to adverts for volunteers.

Inclusion criteria for cases: a current primary diagnosis of DPD and scores \>70 on the Cambridge Depersonalization Scale [@bib43]. All were unresponsive to at least one medication, although the majority had failed to respond to several and had been ill for at least 2 years. Patients taking medications could participate in the trial if their medication did not have safety contraindications with rTMS [@bib44] and if they had been on a stable dose for at least two weeks.

Exclusion criteria were inability to provide informed consent, personal history of severe headaches, a current or historical neurological diagnosis, a personal or family history of seizures or epilepsy, any medical condition involving a loss of consciousness, or the violation of MRI safety contraindications including metal in the body. Participants were screened using the CDS; controls were excluded if they scored \>70.

One patient did not attend her MRI scan due to anxiety and so was not able to continue participation. A further five participants (*N* = 4 with DPD) were excluded from analyses; one patient\'s MRI scan revealed marked cortical atrophy of unknown cause; another could not complete all measures due to technical equipment problems and 3 were because of other protocol violations.

Assessments {#sec2.3}
-----------

Socio-demographic variables were recorded on all subjects. As noted, all subjects completed the CDS, a self-assessment instrument with good reliability and validity, which has state and trait versions. A score of 70 (out of a possible maximum 290, trait version) has a sensitivity of 75.5% and specificity of 87.2% as a clinical cut-off [@bib43]. The CDS has a 'state' version (CDS-S) adapts 22 of the 29 items, which lend themselves to a 'here and now' rating, and uses the mean score expressed as a percentage. The scale has high reliability and has been shown to be sensitive to symptom change [@bib15]. Other scales included the Beck Depression Inventory [@bib45] and Beck Anxiety Inventory [@bib46] and the Dissociative Experiences Scale [@bib47]. All subjects underwent a full psychiatric assessment and duration of illness and treatment history was recorded ([Table 1](#tbl1){ref-type="table"}).

Participants were pseudorandomized to receive either VLPFC or TPJ TMS stimulation with the constraint of ensuring approximately equal numbers in each given the relatively small sample size. They were blind to the study hypotheses and predicted effects of the two stimulation sites. Researchers were not blind to site allocation. Since TPJ could also be therapeutically beneficial for patients but through an unrelated mechanism to that under investigation, it was considered ideal from both an ethical and methodological point of view as an active control [@bib48].

Procedures {#sec2.4}
----------

A structural MRI was obtained for all participants prior to TMS. MRI data were acquired on a GE 1.5 T HDx system (General Electric, Milwaukee, WI, USA) at the Institute of Psychiatry, London. Localizer and calibration scans were followed by 2D T2-weighted Fast Spin Echo and FLAIR (Fluid Attenuated Inversion Recovery) scans. A 3D T1-weighted Inversion Recovery prepared Spoiled Gradient Echo (IR-SPGR) scan was then collected with the following parameters: TE = 5 ms; TR = 12 ms; TI = 300 ms; excitation flip angle = 18°; matrix size 320 × 224 × 220 over a 288 × 202 × 198 field of view, giving an isotropic 0.9 mm voxel size over the whole brain. Images were converted to DICOM format for use within BrainSight-v2 neuronavigation software program. Neuronavigation has been demonstrated to improve the accuracy of positioning a TMS coil [@bib49]. BrainSight ensures that TMS stimulation can only be delivered when the target site is positioned using the frameless stereotaxy.

Skin conductance {#sec2.5}
----------------

Two silver-chloride electrodes 0.5 cm in diameter were attached to the participants\' non-dominant hand at the distal phalanges as per previous research [@bib21]. The SC4 module (Contact Precision Instruments) was used to record skin conductance, attached to a laptop, recording SC signals at 100 mS intervals. Water-soluble electrolyte jelly was used as an electrolyte as per recommended guidelines [@bib50]. These readings were synchronized with a picture presentation.

Stimulus presentation {#sec2.6}
---------------------

An initial set of pictures was shown from the International Affective Picture System (IAPS) [@bib51] in color on a laptop 1 m from the participant prior to rTMS and then the other set, again following rTMS. The two sets, A or B were matched for normative ratings of valence and arousal; participants were randomized to receive either set A or set B of the pictures first. After being asked to sit comfortably for 1 min, and then take a deep sigh (which reliably produces a large SCR), sixteen neutral, non-arousing pictures admixed with and sixteen aversive, emotionally-arousing pictures were shown. Each picture was shown for 2 s, after which the self-assessment manikin (SAM) [@bib52] was shown for 13 s. The SAM uses a cartoon-like dummy, which depicts different states from 1 (feel most aroused) to 9 (feel nothing). Participants were requested to look at the picture, and when the SAM appeared to call out verbally the number on the scale which best fitted "how emotionally provoked \[they\] felt by the picture." SCRs were recording whilst participants looked at the SAM; this period included a 1--4 s post-IAPS image window for event-related SCRs with the remainder allowing recording of spontaneous fluctuations (please see below).

rTMS {#sec2.7}
----

Resting motor threshold (MT) in M1, defined as the lowest intensity of TMS which yielded motor-evoked potentials (MEPs) of at least 50 μV in 5 out of 10 trials using an MEP pod, was determined from electromyographic (EMG) activity in the abductor pollicis brevis using surface electrodes. Co-registration of the participant with their MRI scan and BrainSight version 2 (Rogue Research, Montreal) [@bib53], and coil calibration were performed. 'Target sites' for stimulation using the Simple Point method were set prior to the participant\'s arrival by entering their Talairach coordinates as per their group allocation. The VLPFC coordinates (Right VLPFC *x* = 35, *y* = 25, *z* = −7) were selected to correspond to Brodmann Area (BA)47 which was found to be active in only patients with a diagnosis of DPD in response to aversive scenes in an fMRI task [@bib18]. The TPJ coordinates (Right TPJ *x* = 63, *y* = 37, *z* = 20) were selected as per previous research using neuronavigation, which studied OBEs and self-processing [@bib40] and TMS stimulation of the right TPJ [@bib41]. The coil was held tangential to the scalp of the head with the handle pointing back away from midline at 45°. Participants then received 15 min rTMS delivered at 1Hz and 110% MT to either the right VLPFC or right TPJ, as per their group allocation using a Magstim RMA6802, 3014-00 Rapid² Dual PSU figure-of-eight coil (Magstim Co. Ltd., UK) -- i.e. 900 pulses. Following TMS, outcome measures were completed plus a side-effects checklist, and all participants were debriefed and offered a nominal cash sum for their time and expenses. Finally a semi-structured telephone interview was conducted 24 h later.

Main outcome measures {#sec2.8}
---------------------

In this study, the minimum amplitude of SCRs and SFs measured was 0.04 μS. We recorded three types of electrodermal measure for analysis:(1)*Maximum amplitude of skin conductance deflections*; traditionally used as a key index of individual differences in capacity to generate autonomic activity [@bib50], it measures the highest single deflection in skin conductance recorded across all epochs. We reasoned that increased arousal capacity is likely to coincide with increased reactivity in DPD. We defined the maximum skin conductance as the highest recorded amplitude during any 15 s epoch, during or after stimulus presentation.(2)*Spontaneous fluctuations* (SFs); the number of skin conductance deflections in the absence of an identifiable eliciting stimulus -- a general measure of autonomic reactivity [@bib50]. SFs were recorded following each 2 s picture presentation and outside the 1--4 s event-related window (i.e. the first 1 s and last 9 s of each 15 s epoch).(3)*Event-related SCRs*; electrodermal responses to an identifiable stimulus, including phasic increase in deflection amplitude and changes in latency of response from stimulus onset. The time window was defined as a latency of between 1 and 4 s following the 2 s IAPS picture presentation.

In addition, depersonalization symptoms were measured using the self-report state version of the CDS immediately after TMS. A symptom reduction of at least 25% was considered clinically significant and "responsive" to TMS as per previous research [@bib39]. All outcome measures were recorded pre and post rTMS for comparison.

Statistical analyses {#sec2.9}
--------------------

SPSS version 20 was used for statistical analyses. Analysis of variance (ANOVA) was used to compare post rTMS session outcome measures between those allocated to either VLPFC or TPJ stimulation groups, and in patients and controls. A series of 2 × 2 × 2 mixed model repeated measures ANOVAs was performed for each of the dependent variables: with a within subjects factor: rTMS (pre- and post); and two between groups factors, 'participant group': 'DPD patients' or 'healthy controls' and 'site of stimulation': 'VLPFC' or 'TPJ.' Covariates of BDI, BAI and DES were not used because their variance was not equal across the independent variable [@bib54] but were entered into a multiple regression as potential predictors of outcome. Paired or student\'s *t*-tests were used to explore interactions.

Results {#sec3}
=======

Baseline characteristics of all participants are summarized in [Table 1](#tbl1){ref-type="table"}. There were no significant differences between participants randomized to either VLPFC or TPJ stimulation. Inspection does show that the DPD group was somewhat older and contained fewer females.

Measures of electrodermal activity {#sec3.1}
----------------------------------

In terms of *maximum capacity for SC*, there was a main effect of rTMS (*F*\[1,33\] = 7.3; *P* = 0.01). Maximum SCRs were generally larger post rTMS. However, there was a significant interaction between effects of rTMS, participant group, and site of stimulation (*F*\[1,33\] = 8.2; *P \<* 0.01). Post hoc *t*-tests showed that patients with DPD who received VLPFC rTMS increased their maximum SCR post rTMS (*t* = −2.2, df = 7, *P \<* 0.05) with controls showing no significant change ([Table 2](#tbl2){ref-type="table"}). TPJ rTMS given to DPD patients did not produce any appreciable change while, curiously, it did increase maximum SCR in controls (*t* = −2.1, df = 8, *P* = 0.05) (see [Fig. 1](#fig1){ref-type="fig"}A and B).

In terms of the number of SFs, there were no significant main effects. There was a significant interaction between effect of rTMS and participant group (*F*\[1,33\] = 7.3; *P* = 0.01; see [Table 3](#tbl3){ref-type="table"}; [Fig. 2](#fig2){ref-type="fig"}). From the figure it appears that the interaction reflects the patients\' tendency to show an increase in SFs post rTMS (Paired *t*-tests: *t* = −1.83, df = 16, *P* = 0.08), while controls show a decrease (*t* = 2.11, df = 19, *P* = 0.048).

There was also a suggestion that the 2 sites of TMS may differ although the 3-way interaction between TMS, group and site was not significant. Nevertheless given our *a priori* interest in the effect of VLPFC on autonomic function in DPD we carried out paired *t*-tests which showed a trend increase in patients\' SFs following VLPFC (*t* = −2.11, df = 7, *P* = 0.07) which was much weaker following TPJ stimulation (*P* = 0.4). In sum, rTMS appeared to increase SFs in patients rather than controls and there was a suggestion that this effect was stronger following VLPFC stimulation (see [Fig. 2](#fig2){ref-type="fig"}).

There were no significant differences post rTMS in event-related responses for cases and controls for measures including latency, and 'amplitude' uncorrected and corrected for electrodermal capability (maximum SC).

Subjective rating of depersonalization {#sec3.2}
--------------------------------------

As expected, there was a main effect of participant group (*F*\[1,33\] = 100.3; *P \<* 0.01) with DPD patients scoring higher on the CDS-S than healthy controls: pre-TMS DPD (mean (SD) 42.0 (15.6) vs. controls mean 1.8 (2.7)). There was a main effect of rTMS (*F*\[1,33\] = 21.1; *P \<* 0.01) but no effect of site of stimulation (*F*\[1,33\] = 0.1; *P* = 0.70). There was an interaction between the effect of rTMS and participant group (*F*\[1,33\] = 28.7; *P \<* 0.01; [Table 1](#tbl1){ref-type="table"}; [Fig. 3](#fig3){ref-type="fig"}). Post hoc *t* tests (*t* = 4.8, df = 16, *P \<* 0.01) found that patients with DPD showed a significant decrease in depersonalization symptoms post VLPFC rTMS (CDS-S score 31.3 (14.9)) and TPJ rTMS (CDS-S score 32.1 (17.6)), whereas healthy controls, marginally increased their depersonalization scores post VLPFC rTMS and TPJ rTMS (*t* = −2.2, df = 19, *P* = 0.04) (see [Fig. 3](#fig3){ref-type="fig"}A and B).

Adverse effects {#sec3.3}
---------------

All TMS participants completed the full session and no one chose to discontinue. One experienced a mild headache and another mild difficulties concentrating after rTMS. Three participants experienced "twitching or jerking" sensations and one felt "more present," experiences confined to right VLPFC stimulation. Two experienced 'drunk-like' feelings after right TPJ stimulation.

Multiple regression {#sec3.4}
-------------------

All participants were included in the modeling since scales covered dimensions of psychopathology spanning healthy controls and DPD patient scores. Dependent variables were: maximum SC, SFs and CDS-S scores. Independent variables entered stepwise were: the CDS-Trait score, DES, BDI and BAI scores; gender and age. The results showed that none of the variables influenced maximum SC or SFs in response to rTMS. For the post rTMS CDS-S measure, baseline CDS, DES and BAI scores each contributed significantly to a total variance of 79% with β coefficients of 0.65, 0.46 and 0.22, respectively.

Discussion {#sec4}
==========

The findings support our hypothesis that rTMS to the VLPFC increases autonomic activity in DPD patients. We found that patients with DPD produce a significant increase in the size of their maximum skin conductance response after rTMS but only in the VLPFC condition. Conversely, healthy controls show a different pattern of response, and only increase in their maximum SCRs after TPJ stimulation. We chose to record and analyze maximum SC deflection because it gives a measure of a person\'s capacity to respond autonomically to external or interoceptive stimuli, which has been found attenuated in DPD.

This finding in patients with DPD is suggestive of a disinhibitory effect of right VLPFC rTMS. Previous neuroimaging studies have shown hyperactivation in prefrontal areas in patients with DPD [@bib18; @bib22; @bib23]. Such frontal activation is functionally related to lack of activation in emotion-generation related areas, e.g. the anterior insula [@bib24], and increased frontal activity has been found to be inversely correlated with skin conductance responses [@bib18].

It is not clear why healthy controls show a similar increase on maximum SCRs after TPJ stimulation. A previous study using low frequency rTMS on the right TPJ found a disruptive effect on the subjective sense of embodiment and the distinction between self and not-self, suggesting that the TPJ is actively involved in maintaining a coherent sense of one\'s body distinct from external non-corporeal objects [@bib55].

Spontaneous SC fluctuations (SFs) are considered an overall index of skin conductance reactivity and it has been reported that patients with DPD who go into remission show an increase in SFs [@bib20], akin to the tracings of anxiety patients. Post rTMS there was an increase in patients\' SFs regardless of site while healthy controls tended to show fewer SFs, again, regardless of site. This might be interpreted as evidence of some non-specific arousal following rTMS, which could be beneficial in DPD patients although a modest trend was observed following post-hoc testing for a greater increase following VLPFC rTMS given to DPD patients, in line with our specific predictions.

We measured different parameters of skin conductance during each of the 15-s epochs inside the 1--4 s event-related window for IAPS pictures pre and post rTMS. No significant results were found for amplitude or for latency of SCR. One reason for the lack of change with event-related SCRs could be due to the problem of habituation to the emotional pictures contained in the IAPS -- even though non-identical images were shown pre and post TMS. Few studies have explored the effect of prefrontal TMS on SCRs in general, but one study found that anterior frontal 1Hz rTMS reduced SCRs [@bib56].

Our other main outcome measure was intensity of depersonalization symptoms on the CDS-State version pre and post rTMS. It was found that patients decreased in their scores post rTMS. Controls slightly increased in their scores but they were still way below clinical levels. These findings were irrespective of site of stimulation. The mean reduction in CDS-S scores was 28.8% (27.3 (17.5) and 30.1 (23.3) for VLPFC and TPJ, respectively, *P* = 0.79) and is noteworthy following just a single session of rTMS. Five of eight patients with DPD receiving a single session of right VLPFC stimulation would meet criteria for being a 'partial responder' i.e. showed a 25% reduction in CDS scores post rTMS. In the TPJ condition, results were similar; out of *N* = 9 patients with DPD, *N* = 4 would meet criteria for being a partial responder, and *N* = 1 would be classed as a full responder i.e. showed a 50% reduction in CDS scores post rTMS, according to criteria [@bib39].

In the earliest trial [@bib37], a patient was treated with 1Hz rTMS to the right prefrontal cortex. The next day, she reported dramatic improvement. Although her progress reportedly did not continue in the coming weeks, this is further evidence that after only 1 session significant improvements may be achieved. Another early trial [@bib38], reported a patient with continuous DPD for seven years. Interestingly, 24 h after DLPFC rTMS, a 15% reduction in visual-analogue scales of DPD was reported. After six sessions, a 28% reduction in CDS scores was reported. In the case series [@bib39], patients reported a 35% reduction in symptoms after receiving 3 weeks right-sided TPJ.

These results indicate that, based purely in terms of reduction on CDS-S scores alone, both VLPFC and TPJ stimulation may be beneficial to patients, working via different neurobiological mechanisms relevant to DPD. Patients with DPD sometimes complain of the feeling that their self and body are somehow disconnected and this is akin to feelings of disembodiment, which are provoked by physiological disruption to the TPJ [@bib40; @bib41] and hence could conceivably be ameliorated by rTMS. A recent secondary analysis [@bib57] found that in those patients who benefitted from TPJ stimulation, symptoms of anomalous body experience, as rated from the CDS improved particularly, although emotional numbing also improved. Indeed we found that scores on the CDS state scale item that loads most heavily on emotional numbing ("I am not feeling any emotions at all"), fell following VLPFC but not TPJ stimulation. On the other hand, the item: "... I feel automatic and mechanical, as if I were a robot," fell somewhat more following TPJ stimulation than VLPFC.

Another possibility is that rTMS in both VLPFC and TPJ can affect autonomic arousal -- directly or indirectly -- as indexed by spontaneous fluctuations in electrodermal activity. Interestingly, ventral frontal cortex and TPJ are implicated in network which appears to be specialized in directing attention to salient stimuli [@bib58], and this may even extend to social cognitive functions [@bib59] which may be disrupted in DPD. This might explain who TMS to the 2 sites may produce convergent effects. Subjective improvements such as symptom severity are susceptible to placebo effects. Patients may have high expectations of the treatment, which did not contain a sham condition. Improvement in CDS-S scores was influenced by baseline severity of depersonalization symptoms as well as broader anxiety and dissociative symptoms -- according to the multiple regression analysis -- which could be interpreted as regression to the mean. Nevertheless, it should be noted DPD are notoriously resistant to placebo effects in clinical trials [@bib60].

We were concerned that VLPFC stimulation with rTMS would be poorly tolerated because of the inevitable muscular contraction around the eye. However, pilot work and post-experimental debriefing did not reveal this to be a problem, at least not at the frequencies used. Indeed therapeutic uses of VLPFC rTMS have been reported, such as for tinnitus [@bib61]. Similarly, our findings were specific to right-sided stimulation -- selected again based on previous empirical work but also to avoid potential disruption of language and verbal memory which might follow left side stimulation. Indeed both sites (VLPFC and TPJ) were in the right hemisphere hence we cannot comment on whether left hemisphere stimulation would have had the same therapeutic and physiological effects.

Differences found on key non-event related autonomic variables such as maximum SCRs by site of stimulation, indicates that distinct physiological perturbations were produced by TMS in DPD patients despite transynaptic effects which justifies stereotaxy-guided neuronavigation technology used to improve focality and consistency.

We considered alternative prefrontal sites for TMS stimulation. The DLPFC has been explored extensively in the clinical and non-clinical cognitive neuroscience literature, in part because its accessibility as well as its theoretical importance. As noted, the evidence is stronger for the role of VLPFC in DPD, due, we hypothesized, to its role in emotional control. Ventrolateral, orbito-medial and dorsolateral prefrontal regions each play a role in emotion--cognition interactions [@bib42; @bib62]. DLPFC seems particularly implicated in decision making which is emotionally biased, while more ventral regions modulate (and may inhibit) emotional response. Indeed source localization analyses of ERP data to an emotional go/no-go task [@bib63] revealed right VLPFC activation in affective response inhibition whereas anterior cingulate activation was sensitive to emotional valence but not inhibition. Furthermore, low-frequency rTMS to the right DLPFC combined with H~2~O^15^ positron emission tomography revealed regional cerebral blood flow increases under the stimulation site as well as ipsilateral ventrolateral PFC [@bib64]. Similarly, rTMS to right DLPFC in conjunction with an attention task produced changes detected using fMRI in both ipsi- and contra-lateral VLPFC [@bib65].

Limitations {#sec4.1}
-----------

Increasing the sample size would obviously be desirable to improve statistical power and permit sub-group analyses, although the current study is the first ever case--control comparison and builds on previous case reports and series. Naturally, the healthy controls were unlikely to be comparable with the cases in terms of general psychopathology although when this was considered in the multiple regression, it emerged that the effect of rTMS on the main objective outcome measure, maximum SCR, was not influenced by baseline psychopathology (although change in symptom scores was).

Besides the modest sample size, the other major limitation was the absence of a sham condition. Sham TMS is not however without technical and methodological difficulties [@bib66] although technological advances have facilitated high quality controlled trials. Blinding is hard to maintain and the use of active coils held at 90° to the skull may in fact produce physiological effects. Future coils, which mimic real rTMS sufficiently to blind the participant are likely to be developed. In the absence of this, an alternative active control site could be considered such as occipital cortex, although this can interfere with visual stimuli and produce unwanted sensations.

Conclusion {#sec5}
==========

A single session of right-sided 1Hz rTMS to VLPFC or TPJ stimulation significantly reduces depersonalization symptoms in patients. This procedures resulted in changes in non-event related electrodermal responses namely increased maximum SCR (VLPFC only) and increased SFs, whilst there was no change to event-related responses. Changes in symptoms might reflect physiologically driven improvements in DPD but placebo effects cannot be entirely excluded. These proof-of-concept findings, if replicated in a larger sample, should inform a randomized controlled clinical trial comparing multiples session rTMS at hypothesized therapeutic sites of stimulation (either VLPFC or TPJ) using low frequency neuronavigation-guided rTMS with sham stimulation.
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![(A, B) Maximum skin conductance deflection of depersonalization disorder patients and healthy controls for both VLPFC and TPJ rTMS. DPD patients and controls. VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction; rTMS, repetitive transcranial magnetic stimulation; SE, standard error.](gr1){#fig1}

![Spontaneous fluctuations (SFs) in skin conductance for both depersonalization disorder patients (DP) and healthy controls (C) receiving either VLPFC or TPJ TMS (transcranial magnetic stimulation). VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction.](gr2){#fig2}

![(A, B) Scores on the Cambridge Depersonalization Scale state version pre and post VLPFC and TPJ rTMS. DPD patients and controls. VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction.](gr3){#fig3}

###### 

Baseline characteristics of all participants, DPD patients and controls -- separated according to allocation to TMS condition.

                                   Patients with DPD (*N* = 17)   Healthy controls (*N* = 20)                
  -------------------------------- ------------------------------ ----------------------------- ------------ -------------
  Age, mean (SD)                   34.9 (5.2)                     39.3 (14.6)                   30.1 (4.4)   28.3 (7.0)
  Gender                           7 male                         6 male                        5 male       3 male
  Taking psychotropic medication   3                              5                             0            0
  Duration of DPD (years)          15.1 (9.7)                     12.4 (16.7)                   --           --
  Age of DPD onset                 16.7 (5.9)                     22.3 (15.3)                   --           --
  CDS trait total                  133.9 (29.4)                   119.2 (33.7)                  7.6 (9.6)    20.3 (21.8)
  DES                              30.1 (13.4)                    30.0 (14.2)                   4.3 (2.0)    12.0 (12.3)
  BAI                              40.6 (12.9)                    36.4 (14.0)                   2.3 (1.9)    6.7 (9.4)
  BDI                              22.4 (12.7)                    14.0 (7.9)                    4.5 (3.5)    12.0 (10.1)
  Resting motor threshold          56.4 (4.5)                     52.7 (2.8)                    52.5 (6.2)   51.3 (2.2)
  Baseline SCR (μsiemens)          0.5 (0.8)                      0.6 (0.5)                     0.8 (0.9)    0.7 (0.4)
  Baseline SCL (μsiemens)          3.2 (1.6)                      4.0 (2.3)                     3.2 (2.0)    3.4 (1.4)

DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction; DES, Dissociative Experiences Scale; BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; SCR, skin conductance response; SCL, skin conductance level.

###### 

Maximum capacity for skin conductance response.

  TIME POINT   Depersonalization disorder (*N* = 17)   Healthy controls (*N* = 20)                                             
  ------------ --------------------------------------- ----------------------------- ------------- ------------- ------------- -------------
  Pre TMS      4.66 (2.93)                             5.39 (2.82)                   5.05 (2.81)   4.89 (3.33)   4.58 (2.10)   4.75 (2.78)
  Post TMS     6.37 (4.37)                             5.19 (3.03)                   5.74 (3.65)   4.97 (3.80)   7.05 (3.99)   5.91 (3.93)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Statistical analysis                                                                                                          
  ---------------------- -------------------------------- ------------- --------------------- --------------------------------- ---------------------------------------------------------------------------
  rTMS                   *F*\[1,33\] = 7.25; *P* = 0.01   Pre \< post   rTMS\*\               *F*\[1,33\] = 8.19; *P* \< 0.01   DPD patients who receive VLPFC rTMS show increases in Max. SCR post rTMS\
                                                                        Subject type\*\                                         *t* = −2.15, df = 7, *P* \< 0.05\
                                                                        Site of stimulation                                     Controls who receive TPJ rTMS show increases in Max. SCR post rTMS\
                                                                                                                                *t* = −2.14, df = 8, *P* = 0.05

  Subject type           *F*\[1,33\] = 0.0; *P* = 0.98    NS                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction; rTMS, repetitive transcranial magnetic stimulation; SCR, skin conductance response.

###### 

Spontaneous fluctuations (SFs) in skin conductance.

  Time point   Depersonalization disorder (*N* = 17)   Healthy controls (*N* = 20)                                             
  ------------ --------------------------------------- ----------------------------- ------------- ------------- ------------- -------------
  Pre TMS      2.45 (1.62)                             2.20 (1.64)                   2.32 (1.58)   2.65 (1.16)   3.28 (1.41)   2.93 (1.28)
  Post TMS     3.08 (1.20)                             2.59 (1.59)                   2.82 (1.40)   2.16 (1.02)   2.94 (1.56)   2.51 (1.31)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Statistical analysis                                                        
  ---------------------- ---- ---- --------- -------------------------------- ----------------------------------------------------------------------------------------------------------------
  rTMS                   NS   NS   rTMS\*\   *F*\[1,33\] = 7.27; *P* = 0.01   DPD patients after VLPFC show trend to increase SFs post rTMS: (paired *t*-test)\
                                   Group                                      *t* = −2.11, df = 7, *P* = 0.07; and after TPJ show no increase SFs post rTMS: *t* = −0.85, df = 8, *P* = 0.42

  Group                  NS   NS                                              
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DPD, depersonalization disorder; VLPFC, ventrolateral prefrontal cortex; TPJ, temporo-parietal junction; rTMS, repetitive transcranial magnetic stimulation; SFs, spontaneous fluctuations; SCR, skin conductance response.
